TY - JOUR
T1 - Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing
AU - Singh, Dolly
AU - Dhummakupt, Adit
AU - Siems, Lilly
AU - Persaud, Deborah
N1 - Funding Information:
Financial support. This work was supported by the National Institutes of Health (grant R01 HD080474).
Funding Information:
Supplement sponsorship. This work is part of a supplement sponsored by the National Institute of Allergy and Infectious Disease, NIH, and the Centers for Disease Control and Prevention.
Publisher Copyright:
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Monitoring human immunodeficiency virus type 1 (HIV-1) drug resistance is critical for assessing ART effectiveness and treatment outcomes for HIV-1-infected individuals, including children, worldwide. Traditionally, testing for HIV-1 drug resistance has primarily been performed on plasma samples, and with commercially available, clinically validated assays that are costly and difficult to access. While plasma is the preferred sample for HIV-1 drug resistance genotyping, plasma analysis requires sophisticated laboratory equipment, personnel, space, and stringent storage conditions for maintenance of sample integrity and transport. With the limitations in feasibility and affordability of providing these ideal conditions for plasma genotyping in resource-constrained settings, the field has gained substantial experience with the dried blood spot (DBS) technique as an alternative. Moreover, DBS analysis can be used to comprehensively monitor the spread of the epidemic with applications to more-sensitive and quantitative technologies to assess HIV-1 globally.
AB - Monitoring human immunodeficiency virus type 1 (HIV-1) drug resistance is critical for assessing ART effectiveness and treatment outcomes for HIV-1-infected individuals, including children, worldwide. Traditionally, testing for HIV-1 drug resistance has primarily been performed on plasma samples, and with commercially available, clinically validated assays that are costly and difficult to access. While plasma is the preferred sample for HIV-1 drug resistance genotyping, plasma analysis requires sophisticated laboratory equipment, personnel, space, and stringent storage conditions for maintenance of sample integrity and transport. With the limitations in feasibility and affordability of providing these ideal conditions for plasma genotyping in resource-constrained settings, the field has gained substantial experience with the dried blood spot (DBS) technique as an alternative. Moreover, DBS analysis can be used to comprehensively monitor the spread of the epidemic with applications to more-sensitive and quantitative technologies to assess HIV-1 globally.
KW - Antiretroviral drug resistance.
KW - Dried blood spot
KW - HIV-1
UR - http://www.scopus.com/inward/record.url?scp=85038129776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038129776&partnerID=8YFLogxK
U2 - 10.1093/infdis/jix386
DO - 10.1093/infdis/jix386
M3 - Article
C2 - 29029130
AN - SCOPUS:85038129776
SN - 0022-1899
VL - 216
SP - S834-S837
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -